Established in 2021 by Sonam Kothari and Abhishek Sen, Butterfly Learnings specializes in tailored therapy regimens and extensive support for children and families confronting neurodiversity challenges.
On Thursday, healthtech startup Butterfly Learnings secured Rs 32 crore (approximately $3.8 million) in its Series A funding round, led by Insitor Impact Asia Fund II and Enzia Ventures. CIIE (IIMA Ventures), Foundation Botnar, 9 Unicorns, and Venture Catalysts also joined the investment round.
The company, founded in 2021 by Sonam Kothari and Abhishek Sen, offers personalized therapy regimens and holistic support for children and families encountering neurodiversity challenges. With over 250 trained therapists on staff, Butterfly Learnings operates in Mumbai, Pune, Nagpur, and Nasik.
Their therapy regimens draw from Applied Behavior Analysis (ABA), consultations with pediatric neurologists or developmental pediatricians, and various additional therapies including occupational therapy, speech therapy, oral placement therapy, and sensory integration.
Sonam Kothari, Co-Founder & CEO of Butterfly Learnings, expressed that the funding will advance their mission to deliver accessible and evidence-based pediatric behavioral and developmental health solutions to families nationwide.
The startup previously secured $2 million in its Seed funding round from Insitor Partners, 9 Unicorns, Venture Catalysts, Fondation Botnar, UTIL Stiftung, Enzia Ventures, and CIIE in 2022. The latest funding will be utilized to expand the company’s technology-enabled therapy programs, empowering neurodiverse children to better integrate with society and manage their lives effectively.
Butterfly Learnings currently serves approximately 2,000 families across 30 centers in Maharashtra and intends to broaden its reach across multiple states and cities in India through a network of 200 centers.
Nicholas Lazos, Co-Founder and CIO at Insitor Impact Asia Fund II, highlighted that nearly 3 million children in India are affected by autism, with one in eight children aged between 2–9 experiencing at least one neurodevelopmental disorder.
“Unfortunately, the small number of standalone clinics currently available to parents lack a rigorous scientific approach to therapy provision. Dr. Sonam and Dr. Abhishek have successfully leveraged their extensive clinical and technological expertise to offer an evidence-based, technology-enabled therapy solution for children. We enthusiastically support them in this next phase of growth,” said Lazos.
Read More: Click Here
